

Third-Quarter

2026 Financial Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Achieved key regulatory and clinical milestones



Drove positive momentum across therapeutic areas



Continued to advance broad and diverse pipeline



“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology research presented at the ESMO Congress 2026 further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”

Rob Davis
Chairman and Chief Executive Officer, Merck

Q3 2026

Sales growth reflects continued strength in oncology and animal health, plus contributions from other products in broader portfolio

WORLDWIDE SALES

\$18.1B

GAAP EPS^{1,2}

\$2.04

NON-GAAP EPS^{1,2}

\$2.49

2026 OUTLOOK

Updated ranges for 2026 outlook

WORLDWIDE SALES

\$66.8B
to
\$67.3B

NON-GAAP EPS³

\$2.77
to
\$2.82

Sales



\$8.6B
6% Growth



\$694M
93% Growth



\$1.7B
4% Growth



Q3
2026
Financial Results

¹ A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release.
² GAAP and non-GAAP EPS include a one-time charge of \$0.12 per share related to a global license agreement with SciBrunch Therapeutics Co., Ltd.
³ Outlook now includes a one-time charge of \$0.12 per share related to the global license agreement with SciBrunch Therapeutics Co., Ltd.